Tavio Capital LLC acquired a new stake in shares of Davita Inc (NYSE:DVA) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 206,338 shares of the company’s stock, valued at approximately $11,609,000. Davita makes up about 4.7% of Tavio Capital LLC’s investment portfolio, making the stock its 10th largest position. Tavio Capital LLC owned approximately 0.13% of Davita as of its most recent filing with the Securities and Exchange Commission.
Other large investors have also bought and sold shares of the company. Barings LLC purchased a new stake in Davita during the first quarter valued at about $1,568,000. Campbell & CO Investment Adviser LLC purchased a new stake in Davita during the second quarter valued at about $493,000. GHP Investment Advisors Inc. lifted its stake in Davita by 1.5% during the first quarter. GHP Investment Advisors Inc. now owns 30,265 shares of the company’s stock valued at $1,643,000 after buying an additional 460 shares in the last quarter. Clearbridge Investments LLC lifted its stake in Davita by 63.5% during the first quarter. Clearbridge Investments LLC now owns 798 shares of the company’s stock valued at $43,000 after buying an additional 310 shares in the last quarter. Finally, Northstar Group Inc. lifted its stake in Davita by 33.2% during the second quarter. Northstar Group Inc. now owns 9,082 shares of the company’s stock valued at $511,000 after buying an additional 2,266 shares in the last quarter. Institutional investors own 91.47% of the company’s stock.
Shares of NYSE DVA traded up $1.95 during mid-day trading on Friday, reaching $62.25. The company had a trading volume of 310,075 shares, compared to its average volume of 3,928,074. The stock has a fifty day moving average of $58.24 and a two-hundred day moving average of $54.37. The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.10 and a current ratio of 1.12. The company has a market capitalization of $9.87 billion, a price-to-earnings ratio of 17.43, a PEG ratio of 0.59 and a beta of 1.59. Davita Inc has a 12-month low of $43.40 and a 12-month high of $79.11.
Davita (NYSE:DVA) last posted its quarterly earnings results on Thursday, August 1st. The company reported $1.22 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.10 by $0.12. The business had revenue of $2.84 billion during the quarter, compared to analyst estimates of $2.86 billion. Davita had a net margin of 1.21% and a return on equity of 14.67%. The firm’s revenue was down 1.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.05 earnings per share. Sell-side analysts forecast that Davita Inc will post 4.8 earnings per share for the current fiscal year.
A number of analysts have commented on the stock. Robert W. Baird lowered shares of Davita from an “outperform” rating to a “neutral” rating and reduced their price objective for the company from $70.00 to $65.00 in a research note on Friday, July 26th. SunTrust Banks reaffirmed a “hold” rating and set a $68.00 price objective on shares of Davita in a research note on Wednesday. TheStreet raised shares of Davita from a “c+” rating to a “b-” rating in a research note on Wednesday, July 24th. ValuEngine lowered shares of Davita from a “hold” rating to a “sell” rating in a research note on Tuesday, August 20th. Finally, UBS Group reduced their price objective on shares of Davita from $61.00 to $60.00 and set a “neutral” rating for the company in a research note on Thursday, August 22nd. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and two have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $67.31.
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Further Reading: Front-End Load
Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Davita Inc (NYSE:DVA).
Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.